Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA accepts Ferrer anti-lipid drug MAA for review
The MAA, submitted under the name ‘TESAMORELIN FERRER,’ is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows
The MAA, submitted under the name ‘TESAMORELIN FERRER,’ is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows
to BBB is applying the G- Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3 101. The company expects
Redwood’s technology was launched based on aldehyde tagging which functions as a chemical site on the surface of a protein that can be selectively modified through aldehyde specific
The patient recruitment has been started following the Argentinean approval which permits the company to recruit around eight patients with type 1 diabetes and severe hypoglycaemia. In the
In May this year Sanofi had signed a $613m licensing pact with Glenmark Pharmaceuticals Limited India (GPL) subsidiary Glenmark Pharmaceuticals SA (GPSA) to develop and commercialize a monoclonal
According to animal studies, amifostine protects against genomic instability and associated long term genomic damages resulting from radiation exposure, such as from CT scans and other diagnostic radiology
The company’s sBLA is supported by the results of a Phase 3 Study (‘147) investigating XGEVA versus placebo in 1,432 men with castrate-resistant prostate cancer. The results of
RP101, a first-in-class small molecule addressing chemo resistance in human cancers with initial focus on pancreatic carcinoma, is to be given in a combination with chemotherapy. Recently, RP101
The agreement allows the commercial partner to continue its research cooperation with Dyadic Netherlands, the R&D subsidiary of Dyadic. Additionally, it will use Dyadic’s patented and proprietary C1
Hsp90 is a member of the heat shock protein family which assists in protein folding, cell signaling, and tumor repression and is a novel target for oncology and